HBV/HCV

Two Approvals in Latin America To Market ZADAXIN Thymosin Alpha 1 Received

Published in Vaccine Weekly, March 9th, 1998

SciClone Pharmaceuticals, Inc., San Mateo, California, announced that it has received government approval to market its lead drug, ZADAXIN thymosin alpha 1, in Argentina and Peru.

These ZADAXIN marketing approvals are SciClone's first in Latin America and the company's first outside Asia. ZADAXIN is already marketed in three Asian countries - the People's Republic of China, the Philippines and Singapore. SciClone has filed for approval to market ZADAXIN in 16 additional countries in Asia, the Middle East and Latin America.

Consistent with SciClone's strategic plan to enter Argentina, a lead market in Latin America, as rapidly as possible, ZADAXIN...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1998-03-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry